

OFFICE OF THE SECRETARY OF STATE

LAVONNE GRIFFIN-VALADE
SECRETARY OF STATE

CHERYL MYERS
DEPUTY SECRETARY OF STATE
AND TRIBAL LIAISON



ARCHIVES DIVISION

STEPHANIE CLARK
DIRECTOR

800 SUMMER STREET NE
SALEM, OR 97310
503-373-0701

TEMPORARY ADMINISTRATIVE ORDER
INCLUDING STATEMENT OF NEED & JUSTIFICATION

BP 61-2024

CHAPTER 855
BOARD OF PHARMACY

FILED

08/09/2024 3:06 PM
ARCHIVES DIVISION
SECRETARY OF STATE
& LEGISLATIVE COUNSEL

FILING CAPTION: Temporarily adopts updated protocols for Coronavirus 2019, Influenza (Inactivated & Live), and Respiratory Syncytial Virus

EFFECTIVE DATE: 08/09/2024 THROUGH 02/04/2025

AGENCY APPROVED DATE: 08/08/2024

CONTACT: Rachel Melvin

971-673-0001

pharmacy.rulemaking@bop.oregon.gov

800 NE Oregon St., Suite 150

Portland, OR 97232

Filed By:

Rachel Melvin

Rules Coordinator

NEED FOR THE RULE(S):

Temporarily amends the Coronavirus 2019, Influenza (Inactivated & Live), and Respiratory Syncytial Virus protocols to align with the most current Centers for Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP) recommendations.

JUSTIFICATION OF TEMPORARY FILING:

Failure to amend vaccine protocols in OAR 855-115-0345 to align with CDC ACIP recommendations may result in compromised patient access and care, posing a significant risk to public health by leaving individuals vulnerable to preventable diseases and potentially overwhelming other healthcare providers.

DOCUMENTS RELIED UPON, AND WHERE THEY ARE AVAILABLE:

Proposed Coronavirus 2019 Protocol

https://www.oregon.gov/pharmacy/Documents/PrevCare_IMZ_Coronavirus_19_v.08.2024_DRAFT.pdf

Proposed Influenza (Inactivated) Protocol

https://www.oregon.gov/pharmacy/Documents/PrevCare_IMZ_Influenza_Inactivated_v.08.2024.pdf

Proposed Influenza (Live) Protocol

https://www.oregon.gov/pharmacy/Documents/PrevCare_IMZ_Influenza_Live_Attenuated_v.08.2024.pdf

Proposed Respiratory Syncytial Virus Protocol

https://www.oregon.gov/pharmacy/Documents/PrevCare_IMZ_Respiratory_Syncytial_Virus_v.08.2024.pdf

AMEND: 855-115-0345

RULE SUMMARY: Temporarily adopts amended Coronavirus 2019, Influenza (Inactivated & Live), and Respiratory Syncytial Virus vaccine protocols to align with the most current Centers for Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP) recommendations.

CHANGES TO RULE:

855-115-0345

Services: Prescribing - Protocol Compendium

A Pharmacist may prescribe, according to OAR 855-115-0330 and OAR 855-115-0335, FDA-approved drugs and devices listed in the following compendium, pursuant to a statewide drug therapy management protocol. ¶

(1) Continuation of therapy including emergency refills of insulin and early refills of opioid use disorder medications (v. 08/2024)¶

(2) Conditions¶

(a) Cough and cold symptom management¶

(A) Benzonatate (v. 06/2021);¶

(B) Short-acting beta agonists (v. 06/2021);¶

(C) Intranasal corticosteroids (v. 06/2021);¶

(b) Vulvovaginal candidiasis (VVC) (v. 06/2021);¶

(c) COVID-19 Antigen Self-Test (v. 12/2021);¶

(d) SARS-CoV-2 Antiviral (v. 08/2024)¶

(3) Preventative care¶

(a) Emergency Contraception (v. 06/2021);¶

(b) Male and female condoms (v. 06/2021);¶

(c) Tobacco Cessation, NRT (Nicotine Replacement Therapy) and Non-NRT (v. 06/2024);¶

(d) Travel Medications (v. 06/2024);¶

(e) HIV Post-exposure Prophylaxis (PEP) (v. 06/2023);¶

(f) HIV Pre-exposure Prophylaxis (PrEP) (v.06/2023); ¶

(g) Contraception (v. 06/2023);¶

(h) Sexually Transmitted Infections Post-exposure Prophylaxis (STI PEP) (v. 06/2024);¶

(i) Short-acting Opioid Antagonists (v. 06/2024); and¶

(j) Vaccines:¶

(A) Standard Protocol for All Vaccines: Cover Page & Assessment and Treatment Care Pathway (v. 06/2024); ¶

(B) Standard Protocol for All Vaccines: Managing Adverse Reactions (v. 06/2024); ¶

(C) Cholera (v. 02/2024); ¶

(D) Coronavirus 2019 (v. 068/2024); ¶

(E) Haemophilus Influenza type b (v. 06/2024);¶

(F) Hepatitis A containing vaccines (v. 02/2024); ¶

(G) Hepatitis B containing vaccines (v. 02/2024); ¶

(H) Human Papillomavirus (v. 02/2024); ¶

(I) Influenza - Inactivated Influenza Vaccines and Recombinant Influenza Vaccines 20234-24025 (v. 068/2024); ¶

(J) Influenza - Live Attenuated Influenza Vaccine 20234-24025 (v. 028/2024); ¶

(K) Japanese Encephalitis (v. 06/2024); ¶

(L) Meningococcal containing vaccines (v. 06/2024); ¶

(M) Measles Mumps & Rubella containing vaccines (v. 02/2024); ¶

(N) Pneumococcal (v. 06/2024); ¶

(O) Polio (v. 06/2024);¶

(P) Rabies (v. 02/2024); ¶

(Q) Respiratory Syncytial Virus (v. 068/2024);¶

(R) Tetanus Diphtheria containing vaccines (v. 06/2024);¶

(S) Typhoid (v. 02/2024); ¶

(T) Varicella containing vaccines (v. 02/2024);¶

(U) Yellow fever (v. 06/2024); and¶

(V) Zoster (v. 02/2024).¶

[Publications: Publications referenced are available from the agency.]

Statutory/Other Authority: ORS 689.205, 2024 HB 4002, 2024 SB 1506

Statutes/Other Implemented: ORS 689.645, ORS 689.649, ORS 689.689, 2024 HB 4002, 2024 SB 1506